P01889 (HLAB_HUMAN) Homo sapiens (Human)
HLA class I histocompatibility antigen, B alpha chain UniProtKBInterProInteractive Modelling
362 aa; Sequence (Fasta) ;
1 identical sequence: Homo sapiens: E5FQ95
Available Structures
236 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Seq id (%) | Ligands | |
|---|---|---|---|---|---|---|
| Crystal structure of HLA-B*07:02 with R140Q mutant IDH2 peptide |
Heteromer P48735; P61769; | 100 | 1×K; 2×NA; | |||
| HLA class I micropolymorphisms determine peptide-HLA landscape and dictate differential HIV-1 escap… |
Heteromer P03407; P61769; | 98.19 | 26×EDO; 4×GOL; | |||
| HLA class I micropolymorphisms determine peptide-HLA landscape and dictate differential HIV-1 escap… |
Heteromer P04585; P61769; | 98.19 | 7×EDO; | |||
| HLA class I micropolymorphisms determine peptide-HLA landscape and dictate differential HIV-1 escap… |
Heteromer P61769; P69726; | 97.83 | 12×EDO; 1×SO4; 1×GOL; | |||
| HLA class I micropolymorphisms determine peptide-HLA landscape and dictate differential HIV-1 escap… |
Heteromer P03407; P61769; | 97.83 | 12×EDO; 2×GOL; | |||
| HLA B8 in complex with an Epstein Barr Virus determinant |
Heteromer P12977; P61769; | 95.54 | 1×CD; | |||
| HLA class I micropolymorphisms determine peptide-HLA landscape and dictate differential HIV-1 escap… |
Heteromer P04585; P61769; | 97.83 | 6×EDO; 1×GOL; 1×SO4; | |||
| DECAMER-LIKE CONFORMATION OF A NANO-PEPTIDE BOUND TO HLA-B3501 DUE TO NONSTANDARD POSITIONING OF TH… |
Heteromer P61769; | 92.06 | ||||
| The crystal structure of LC13 TcR in complex with HLAB8-EBV peptide complex |
Heteromer P01848; P01850; P61769; Q3KST2; | 95.67 | ||||
| Crystal structure of an anaplastic lymphoma kinase-derived neuroblastoma tumor antigen bound to the… |
Heteromer P61769; Q9UM73; | 93.14 | 7×GOL; 5×SO4; | |||
| COMPLEX RECOGNITION OF THE SUPERTYPIC BW6-DETERMINANT ON HLA-B AND-C MOLECULES BY THE MONOCLONAL AN… |
Heteromer P03204; P61769; | 91.7 | ||||
| Crystal Structure of CF34 TCR in complex with HLA-B8/FLR |
Heteromer P01848; P01850; P61769; | 95.67 | 5×CD; 6×CL; 6×NA; | |||
| Crystal structure of the RL42 TCR in complex with HLA-B8-FLR |
Heteromer P01848; P61769; Q3KST2; | 95.67 | ||||
| DECAMER-LIKE CONFORMATION OF A NANO-PEPTIDE BOUND TO HLA-B3501 DUE TO NONSTANDARD POSITIONING OF TH… |
Heteromer P61769; | 92.06 | ||||
| HLA-B*2709 BOUND TO NONA-PEPTIDE M9 |
Heteromer P61769; | 92.75 | 2×GOL; | |||
| Crystal structure of HLA-B*2709 complexed with the glucagon receptor (GR) peptide (residues 412-420) |
Heteromer P47871; P61769; | 92.75 | 3×GOL; | |||
| Crystal Structure of HLA-B*18:01 in complex with NP338 influenza peptide |
Heteromer P61769; | 93.48 | ||||
| Crystal structure of a peptide-HLA complex |
Heteromer P03206; P61769; | 95.65 | 2×ACT; 1×NA; | |||
| Crystal Structure of HLA B*3508 in complex with a HCMV 8-mer peptide from the pp65 protein |
Heteromer P18139; P61769; | 92.39 | ||||
| Crystal Structure of HLA-B*37:01 in complex with NP338 influenza peptide |
Heteromer P61769; | 90.94 | 2×ACT; | |||
| Crystal Structure of HLA-B*44:05 in complex with NP338 influenza peptide |
Heteromer P61769; | 89.13 | 1×ACT; | |||
| Crystal Structure of HLA-B*2705-W60A in complex with LRN, a self-peptide |
Heteromer P37268; P61769; | 92.39 | ||||
| Crystal Structure of HLA-B8 in complex with ELR, an Influenza A virus peptide |
Heteromer P61769; | 95.29 | ||||
| Crystal Structure of HLA B*0801 in complex with ELK_IYM, ELKRKMIYM |
Heteromer P61769; Q9YRL3; | 95.65 | 2×ACT; | |||
| Crystal Structure of HLA B*0801 in complex with ELN_YYM, ELNRKMIYM |
Heteromer P61769; Q9YRL8; | 95.65 | 1×EDO; | |||
| Crystal structure of hla-b*2705 complexed with the glucagon receptor (gr) peptide (residues 412-420) |
Heteromer P47871; P61769; | 92.75 | 6×GOL; 1×NA; | |||
| HLA-B*1801 in complex with a self-peptide, DELEIKAY |
Heteromer P61769; | 93.48 | 1×ACT; | |||
| Crystal structure of HLA-B*27:05 complexed with the self-peptide pVIPR |
Heteromer P32241; P61769; | 92.75 | 4×GOL; | |||
| Crystal Structure of HLA-B*2705 in complex with LRN, a self-peptide |
Heteromer P37268; P61769; | 92.75 | ||||
| Crystal Structure of HLA-B*2703-P47G in complex with LRN, a self-peptide |
Heteromer P37268; P61769; | 92.03 | ||||
| CRYSTAL STRUCTURE OF HLA-B*2705 COMPLEXED WITH THE VASOACTIVE INTESTINAL PEPTIDE TYPE 1 RECEPTOR (V… |
Heteromer P32241; P61769; | 92.75 | 5×GOL; 1×MN; | |||
| Conformational Restraints and Flexibility of 14-Meric Peptides in Complex with HLA-B*3501 |
Heteromer P61769; | 92.03 | ||||
| Structure of HLA-B*40:02 in complex with the phosphorylated endogenous peptide REF(p)SKEPEL |
Heteromer P61769; Q9NQS7; | 93.48 | 1×EDO; | |||
| Crystal structure of HLA-B*3508 presenting 13-mer EBV antigen LPEPLPQGQLTAY |
Heteromer P61769; | 92.39 | ||||
| HLA-B*18:01 in complex with Epstein-Barr virus BZLF1-derived peptide (residues 173-180) |
Heteromer P61769; Q3KSS8; | 93.48 | 1×ACT; | |||
| Crystal Structure of HLA-B*2703 in complex with KK10, an HIV peptide |
Heteromer P04585; P61769; | 92.39 | 1×MG; | |||
| Crystal Structure of HLA-B*2703 in complex with LRN, a self-peptide |
Heteromer P37268; P61769; | 92.39 | ||||
| CRYSTAL STRUCTURE OF HLA-B*2705 COMPLEXED WITH THE LATENT MEMBRANE PROTEIN 2 PEPTIDE (LMP2)OF EPSTE… |
Heteromer P13285; P61769; | 92.75 | 4×GOL; | |||
| crystal structure of HLA B*3508 LPEP-P9Ala, peptide mutant P9-ala |
Heteromer P61769; | 92.39 | ||||
| Crystal Structure of HLA-B*37:01 in complex with NP338-L7S influenza peptide |
Heteromer P61769; | 90.94 | ||||
| Crystal Structure of HLA-B*37:01 in complex with NP338-V6L influenza peptide |
Heteromer P61769; | 90.94 | ||||
| Crystal Structure of HLA-B*57:01 with an HIV peptide RKV |
Heteromer P04578; P61771; | 89.86 | ||||
| Crystal Structure of HLA-B8 in complex with QIK, a CMV peptide |
Heteromer P61769; | 95.51 | ||||
| HLA class I micropolymorphisms determine peptide-HLA landscape and dictate differential HIV-1 escap… |
Heteromer P04585; P61769; | 100 | 11×EDO; 3×GOL; | |||
| Structure of a nested set of N-terminally extended MHC I-peptides provides novel insights into anti… |
Heteromer P61769; | 95.29 | ||||
| Crystal Structure of HLA B2705-KK10 |
Heteromer P03366; P61769; | 92.75 | 1×GOL; | |||
| Crystal structure of B*27:04 complex bound to the pVIPR peptide |
Heteromer P32241; P61769; | 93.12 | 4×GOL; 1×CL; | |||
| Crystal Structure of HLA B2705-KK10-L6M |
Heteromer P03366; P61769; | 92.75 | 1×TRS; | |||
| Crystal structure of HLA-B*3501 presenting 13-mer EBV antigen LPEPLPQGQLTAY |
Heteromer P61769; | 92.03 | ||||
| Crystal Structure of HLA B*4402 in complex with EEYLKAWTF, a mimotope |
Heteromer P61769; | 88.77 | ||||
| Crystal Structure of HLA B*4402 in complex with HLA DPA*0201 peptide |
Heteromer P61769; Q95HB9; | 88.77 | ||||
| Crystal structure of the HLA-B8-A66-FLR, mutant A66 of the HLA B8 |
Heteromer P61769; Q3KST2; | 95.24 | 1×NA; | |||
| Crystal Structure of HLA-B7 in complex with TPR, a CMV peptide |
Heteromer P61769; | 100 | 4×IOD; 1×NA; 4×CL; 1×PEG; 1×ZN; | |||
| Crystal Structure of HLA B*0801 in complex with ELR_MYM, ELRRKMMYM |
Heteromer P03169; P61769; | 95.65 | 2×ACT; | |||
| Crystal Structure of HLA-B*4403 presenting 10mer EBV antigen |
Heteromer P03204; P61769; | 88.77 | 4×ACT; 2×GOL; | |||
| Crystal Structure of HLA-B7 in complex with RPP, an EBV peptide |
Heteromer P12977; P61769; | 100 | ||||
| HLA-B*58:01 presenting LSSPVTKSW |
Heteromer P61769; | 89.49 | ||||
| Crystal structure of a HLA-B*35:01-HPVG-A4 |
Heteromer P61769; Q1HVF7; | 92.03 | 1×ACT; | |||
| crystal structure of HLA B*3508 LPEP-P7Ala, peptide mutant P7-ala |
Heteromer P61769; | 92.39 | ||||
| Crystal structure of HLA-B35 in complex with a pepetide antigen |
Heteromer P04585; P61769; | 91.67 | ||||
| Crystal structure of an anaplastic lymphoma kinase-derived neuroblastoma tumor antigen bound to the… |
Heteromer P61769; | 93.12 | ||||
| Crystal Structure Of HLA-B*3501 Presenting an 11-Mer EBV Antigen EPLPQGQLTAY |
Heteromer P03206; P61769; | 92.03 | ||||
| Crystal structure of HLA-B*4402 in complex with the F7A mutant of a self-peptide derived from DPA*0… |
Heteromer P61769; Q95HB9; | 88.77 | 4×GOL; | |||
| Crystal Structure of HLA B*0801 in complex with HSKKKCDEL |
Heteromer P61769; X2G898; | 95.54 | ||||
| A natural selected dimorphism in HLA B*44 alters self, peptide reportoire and T cell recognition. |
Heteromer P61769; Q95HB9; | 88.77 | 2×ACY; | |||
| HLA-B*4405 complexed to the dominant self ligand EEFGRAYGF |
Heteromer P61769; Q9TQB0; | 89.13 | ||||
| Crystal structure of HLA-B*3508 presenting EBV peptide EPLPQGQLTAY at 1.7A |
Heteromer P61769; | 92.39 | ||||
| Crystal Structure of B*4402 presenting a 10mer EBV epitope |
Heteromer P03204; P61769; | 88.77 | 9×ACT; 2×GOL; | |||
| CRYSTAL STRUCTURE OF HLA-B*2709 COMPLEXED WITH THE LATENT MEMBRANE PROTEIN 2 PEPTIDE (LMP2) OF EPST… |
Heteromer P13285; P61769; | 92.75 | 5×GOL; | |||
| Crystal structure of HLA-B*2709 complexed with a variant of the latent membrane protein 2 peptide (… |
Heteromer P61769; | 92.39 | 6×GOL; 1×TRS; 1×MES; | |||
| Crystal Structure of HLA B*3508 in complex with a HCMV 12-mer peptide from the pp65 protein |
Heteromer P18139; P61769; | 92.39 | ||||
| HLA-B*57:01 presenting TSTFEDVKILAF |
Heteromer P61769; Q6YHU6; | 89.86 | 3×GOL; 1×ACT; | |||
| Crystal Structures of HLA-B*1501 in Complex with Peptides from Human UbcH6 and Epstein-Barr Virus E… |
Heteromer P51965; P61769; | 93.12 | 2×SO4; 1×URE; 1×GOL; | |||
| Crystal structure of HLA-B*4402 in complex with the F3A mutant of a self-peptide derived from DPA*0… |
Heteromer P61769; Q95HB9; | 88.77 | 1×ACT; 1×GOL; | |||
| HLA-B*57:03 presenting LTVQVARVW |
Heteromer P61769; | 89.86 | ||||
| HLA-B*57:01 presenting LTVQVARVW |
Heteromer P61769; | 89.86 | ||||
| The Immunogenicity of a Viral Cytotoxic T Cell Epitope is controlled by its MHC-bound Conformation |
Heteromer P03206; P61769; | 92.39 | 2×ACY; | |||
| HLA-B*58:03 presenting LTVQVARVY |
Heteromer P61769; | 89.86 | ||||
| Structure of HLA-B*40:02 in complex with the endogenous peptide REFSKEPEL |
Heteromer P61769; Q9NQS7; | 93.84 | ||||
| Crystal structure of the HLA-B8FLRGRAYVL, mutant G8V of the FLR peptide |
Heteromer P61769; Q3KST2; | 95.56 | ||||
| Crystal Structure of HLA B*3501 in complex with influenza NP418 epitope from 1934 strain |
Heteromer P61769; | 92.03 | ||||
| Crystal Structure of HLA B*3501 in complex with influenza NP418 epitope from 1972 strain |
Heteromer P61769; | 92.03 | ||||
| Crystal Structure of HLA B*3501 in complex with influenza NP418 epitope from 1977 strain |
Heteromer P61769; | 92.03 | ||||
| Crystal Structure of hla-b*2705 Complexed with the Citrullinated Vasoactive Intestinal Peptide Type… |
Heteromer P32241; P61769; | 92.75 | ||||
| The high resolution crystal structure of HLA-B*2709 in complex with a Cathepsin A signal sequence p… |
Heteromer P10619; P61769; | 92.75 | 1×GOL; | |||
| Crystal structure of HLA-B*0801.N80I |
Heteromer P61769; | 95.29 | ||||
| Crystal structure of a HLA-B*35:01-HPVG-D5 |
Heteromer P61769; Q3KSS4; | 92.03 | ||||
| Crystal Structure of HLA-B7 in complex with SPI, an influenza peptide |
Heteromer P61769; | 100 | ||||
| Crystal structure of B*27:06 bound to the pVIPR peptide |
Heteromer P32241; P61769; | 93.84 | 2×GOL; | |||
| HLA-B*57:01 presenting GSFDYSGVHLW |
Heteromer P61769; | 89.86 | ||||
| Crystal Structure of HLA B*4405 in complex with EEYLKAWTF, a mimotope |
Heteromer P61769; | 89.13 | ||||
| crystal structure of HLA B*3508LPEP-P5Ala , peptide mutant P5-ala |
Heteromer P61769; | 92.39 | ||||
| The high resolution crystal structure of HLA-B*2705 in complex with a Cathepsin A signal sequence p… |
Heteromer P10619; P61769; | 92.75 | 2×GOL; | |||
| Citrullination-dependent differential presentation of a self-peptide by HLA-B27 subtypes |
Heteromer P32241; P61769; | 92.75 | 6×GOL; | |||
| Crystal Structure of a SARS Corona Virus Derived Peptide Bound to the Human Major Histocompatibilit… |
Heteromer P61769; | 93.12 | 1×PG4; 1×EPE; | |||
| HLA-B*57:01 presenting TSMSFVPRPW |
Heteromer P61769; | 89.86 | ||||
| HLA-B*2709 bound to deca-peptide s10R |
Heteromer P61769; | 92.75 | 1×GOL; | |||
| Crystal Structure of C12C TCR-HLAB2705-KK10-L6M |
Heteromer P03366; P61769; | 92.75 | 3×SO4; | |||
| HLA-B*57:01 presenting LTVQVARVY |
Heteromer P61769; | 89.86 | ||||
| Crystal structure of HLA-B*3501 presenting the human cytochrome P450 derived peptide, KPIVVLHGY |
Heteromer P33260; P61769; | 92.03 | ||||
| Crystal Structure of HLA B*4405 in complex with EEYLQAFTY a self peptide from the ABCD3 protein |
Heteromer P61769; | 89.13 | 2×PEG; | |||
| Crystal Structure of HLA B*3501 in complex with influenza NP418 epitope from 1980 strain |
Heteromer P61769; | 92.03 | ||||
| HLA-B*57:01 presenting LALLTGVRW |
Heteromer P61769; | 89.86 | ||||
| HLA-B*44:03 in complex with Epstein-Barr virus BZLF1-derived peptide (residues 169-180) |
Heteromer P61769; Q3KSS8; | 88.77 | 1×GOL; 2×ACT; | |||
| Crystal structure of HLA-B*27:05 complexed with the self-peptide pVIPR and Copper |
Heteromer P32241; P61769; | 92.75 | 2×CU; 2×GOL; | |||
| Crystal structure of HLA-B*27:05 complexed with the self-peptide pVIPR measured at 295 K |
Heteromer P32241; P61769; | 92.75 | ||||
| Crystal structure of HLA-B*2705 complexed with a peptide derived from the human voltage-dependent c… |
Heteromer P61769; Q01668; | 92.75 | 3×GOL; | |||
| crystal structure of HLA B*3508LPEP-P6Ala, peptide mutant P6-ala |
Heteromer P61769; | 92.39 | ||||
| Crystal structure of HLA-B*2709 complexed with the double citrullinated vasoactive intestinal pepti… |
Heteromer P32241; P61769; | 92.75 | ||||
| Crystal structure of HLA-B*27:05 complexed with the self-peptide pVIPR and Nickel |
Heteromer P32241; P61769; | 92.75 | 2×NI; 2×GOL; | |||
| Crystal Structure of HLA B*4402 in complex with EEYLQAFTY a self peptide from the ABCD3 protein |
Heteromer P61769; | 88.77 | ||||
| HLA-B*07:02 in complex with 229E-derived coronavirus nucleocapsid peptide N75-83 |
Heteromer P15130; P61769; | 100 | 7×ZN; 1×NA; 8×CL; 8×K; 1×BR; | |||
| HLA-B*57:01 presenting LSSPVTKSW |
Heteromer P61769; | 89.86 | ||||
| The Immunogenicity of a Viral Cytotoxic T Cell Epitope is controlled by its MHC-bound Conformation |
Heteromer P03206; P61769; | 92.03 | 2×ACY; | |||
| HLA-B*58:01 presenting LTVQVARVW |
Heteromer P61769; | 89.49 | ||||
| MHC CLASS I MOLECULE B*3501 COMPLEXED WITH PEPTIDE VPLRPMTY FROM THE NEF PROTEIN (75-82) OF HIV1 |
Heteromer P61769; | 91.67 | ||||
| Crystal Structure of HLA B*3501 in complex with influenza NP418 epitope from 1918 strain |
Heteromer P61769; | 92.03 | ||||
| Crystal Structure of HLA B*3501 in complex with influenza NP418 epitope from 2009 H1N1 swine origin… |
Heteromer P61769; | 92.03 | ||||
| The structure of HLA-B*35:01 in complex with the peptide (RPQVPLRPMTY) |
Heteromer P61769; Q9YYU8; | 92.03 | ||||
| Crystal structures and KIR3DL1 recognition of three immunodominant viral peptides complexed to HLA-… |
Heteromer P61769; Q98Y46; | 92.75 | ||||
| Crystal structure of HLA-B*0801.N80I.R82L.G83R |
Heteromer P61769; | 94.56 | ||||
| Crystal Structure of the TK3 TCR in complex with HLA-B*3501/HPVG |
Heteromer P03211; P61769; | 92.03 | 1×SO4; | |||
| Crystal Structure of HLA B*4403 in complex with EEYLQAFTY a self peptide from the ABCD3 protein |
Heteromer P61769; | 88.77 | ||||
| Crystal structure of HLA-B*5801 complex with HIV-1 gag derived peptide TW10 |
Heteromer P03366; P61769; | 89.49 | ||||
| HLA-B*57:01 presenting LSDSTARDVTW |
Heteromer P61769; | 89.86 | ||||
| ANTAGONIST HIV-1 GAG PEPTIDES INDUCE STRUCTURAL CHANGES IN HLA B8-HIV-1 GAG PEPTIDE (GGKKKYKL-INDEX… |
Heteromer P61769; | 95.65 | ||||
| HLA class I micropolymorphisms determine peptide-HLA landscape and dictate differential HIV-1 escap… |
Heteromer P03407; P61769; | 97.83 | 2×GOL; 6×EDO; 2×SO4; | |||
| HLA class I micropolymorphisms determine peptide-HLA landscape and dictate differential HIV-1 escap… |
Heteromer P03407; P61769; | 100 | 3×GOL; 3×EDO; 1×SO4; | |||
| HLA-B*2705 bound to nona-peptide m9 |
Heteromer P61769; | 92.75 | ||||
| Crystal structure of HLA-B*4402 in complex with the R5A mutant of a self-peptide derived from DPA*0… |
Heteromer P61769; Q95HB9; | 88.77 | 2×ACT; 5×GOL; | |||
| Crystal structures and KIR3DL1 recognition of three immunodominant viral peptides complexed to HLA-… |
Heteromer P03466; P61769; | 92.75 | ||||
| Crystal Structure of B*4405 presenting a 10mer EBV epitope |
Heteromer P03204; P61769; | 89.13 | 2×GOL; | |||
| Crystal Structure of the TK3-Gln55His TCR in complex with HLA-B*3501/HPVG |
Heteromer P03211; P61769; | 92.03 | 1×SO4; | |||
| THE THREE-DIMENSIONAL STRUCTURE OF HLA-B27 AT 2.1 ANGSTROMS RESOLUTION SUGGESTS A GENERAL MECHANISM… |
Heteromer P61769; | 92.75 | ||||
| ANTAGONIST HIV-1 GAG PEPTIDES INDUCE STRUCTURAL CHANGES IN HLA B8-HIV-1 GAG PEPTIDE (GGKKKYQL-7Q MU… |
Heteromer P61769; | 95.65 | ||||
| Crystal structure of HLA-B*2705 complexed with the double citrullinated vasoactive intestinal pepti… |
Heteromer P32241; P61769; | 92.75 | ||||
| Crystal Structure Of HLA-B*2709 Complexed With the self-Peptide TIS from EGF-response factor 1 |
Heteromer P47974; P61769; | 92.75 | 2×GOL; | |||
| Crystal structure of HLA-B5801, a protective HLA allele for HIV-1 infection |
Heteromer P04591; P61769; | 89.86 | ||||
| Crystal structure of HLA-B*57:01.I80N.L82R.R83G |
Heteromer P01834; P61769; | 90.94 | ||||
| Crystal structure of the 'restriction triad' mutant of HLA B*3508, beta-2-microglobulin and EBV pep… |
Heteromer P03206; P61769; | 92.03 | 7×ACY; 1×GOL; 8×PEG; | |||
| ANTAGONIST HIV-1 GAG PEPTIDES INDUCE STRUCTURAL CHANGES IN HLA B8-HIV-1 GAG PEPTIDE (GGKKRYKL-5R MU… |
Heteromer P61769; | 95.65 | ||||
| Crystal structure of HLA-B*2709 complexed with the vasoactive intestinal peptide type 1 receptor (V… |
Heteromer P32241; P61769; | 92.75 | 3×GOL; 1×MN; | |||
| Nonstandard peptide binding of HLA-B*5101 complexed with HIV immunodominant epitope KM1(LPPVVAKEI) |
Heteromer P24740; P61769; | 90.94 | ||||
| ANTAGONIST HIV-1 GAG PEPTIDES INDUCE STRUCTURAL CHANGES IN HLA B8-HIV-1 GAG PEPTIDE (GGRKKYKL-3R MU… |
Heteromer P61769; | 95.65 | ||||
| HLA B7:02 with RPIIRPATL |
Heteromer P04666; P61769; | 100 | 7×EDO; | |||
| Crystal Structure Of HLA-B*2705 Complexed With the self-Peptide TIS from EGF-response factor 1 |
Heteromer P47974; P61769; | 92.75 | 2×GOL; | |||
| Crystal Structures of HLA-B*1501 in Complex with Peptides from Human UbcH6 and Epstein-Barr Virus E… |
Heteromer P12977; P61769; | 93.12 | 1×PG4; 1×URE; 2×GOL; | |||
| ANTAGONIST HIV-1 GAG PEPTIDES INDUCE STRUCTURAL CHANGES IN HLA B8-HIV-1 GAG PEPTIDE (GGKKKYRL-7R MU… |
Heteromer P61769; | 95.65 | ||||
| MHC CLASS I MOLECULE B*5301 COMPLEXED WITH PEPTIDE TPYDINQML FROM GAG PROTEIN OF HIV2 |
Heteromer P61769; | 89.86 | ||||
| MHC CLASS I MOLECULE B*5301 COMPLEXED WITH PEPTIDE LS6 (KPIVQYDNF) FROM THE MALARIA PARASITE P. FAL… |
Heteromer P61769; | 89.86 | ||||
| Crystal Structure of HLA B*4403 in complex with EEYLKAWTF, a mimotope |
Heteromer P61769; | 88.77 | ||||
| Crystal structures and KIR3DL1 recognition of three immunodominant viral peptides complexed to HLA-… |
Heteromer P03204; P61769; | 92.75 | ||||
| crystal structure of HLA B*3508 LPEP-P10Ala, peptide mutant P10-ala |
Heteromer P61769; | 92.39 | ||||
| Crystal Structure of C12C TCR-HA B2705-KK10 |
Heteromer P03366; P61769; | 92.75 | ||||
| Crystal structure of HLA-B*4402 in complex with the F3A/R5A double mutant of a self-peptide derived… |
Heteromer P61769; Q95HB9; | 88.77 | 1×ACT; | |||
| Crystal structure of HLA, B*4403, and peptide EEPTVIKKY |
Heteromer P61769; Q9Y5X3; | 88.77 | ||||
| Crystal structure of HLA-B*27:09 complexed with the self-peptide pVIPR and Copper |
Heteromer P32241; P61769; | 92.75 | 3×CU; | |||
| Crystal Structure of SB27 TCR in complex with HLA-B*3508-13mer peptide |
Heteromer P01848; P01850; P03206; P61769; | 92.39 | 7×IOD; | |||
| Crystal structure of HLA-B5801, a protective HLA allele for HIV-1 infection |
Heteromer P04585; P61769; | 89.86 | ||||
| Crystal structure of HLA-B*4402 in complex with the R5A/F7A double mutant of a self-peptide derived… |
Heteromer P61769; Q95HB9; | 88.77 | 1×GOL; | |||
| Crystal Structure of the LC13 TCR in complex with HLA B*4405 bound to EEYLKAWTF a mimotope |
Heteromer P01848; P01850; P61769; | 89.13 | ||||
| Crystal Structure of the LC13 TCR in complex with HLA B*4405 bound to EEYLQAFTY a self peptide from… |
Heteromer P01848; P01850; P61769; | 89.13 | ||||
| Crystal structure of ELS4 TCR bound to HLA-B*3501 presenting EBV peptide EPLPQGQLTAY at 1.7A |
Heteromer P01848; P01850; P03206; P61769; | 92.03 | ||||
| Crystal Structure of the TK3-Gln55Ala TCR in complex with HLA-B*3501/HPVG |
Heteromer P03211; P61769; | 92.03 | 1×SO4; | |||
| Crystal structure of pHLA-B35 in complex with TU55 T cell receptor |
Heteromer P04585; P61769; | 91.67 | 3×GOL; | |||
| Crystal structure of HLA-B*5701 complex with HIV-1 gag derived peptide TW10 |
Heteromer P03366; P61769; | 89.86 | ||||
| HLA-B*07:02 in complex with SARS-CoV-2 nucleocapsid peptide N105-113 |
Heteromer P0DTC9; P61769; | 100 | 3×CL; | |||
| Crystal structure of HLA-B5801, a protective HLA allele for HIV-1 infection |
Heteromer P04591; P61769; | 89.86 | ||||
| Crystal Structure of HLA B*0801 in complex with HSKKKCDEL and DD31 TCR |
Heteromer P61769; X2G898; | 95.65 | 3×IOD; 1×NA; | |||
| Crystal structure of HLA-B*07:02 with R140Q mutant IDH2 peptide in complex with Fab |
Heteromer P48735; P61769; | 100 | 6×PEG; 1×NHE; 8×SO4; | |||
| T cell response to a HIV reverse transcriptase epitope presented by the protective allele HLA-B*51:… |
Heteromer K7N5M3; P01850; P61769; R4WL38; | 90.94 | ||||
| Crystal Structure of EM2 TCR in complex with HLA-B*37:01-NP338 |
Heteromer P61769; | 90.94 | ||||
| Crystal Structure of HLA B*3501-IPS in complex with a Delta-Beta TCR, clone 12 TCR |
Heteromer P18139; P61769; | 92.03 | ||||
| Nonstandard peptide binding of HLA-B*5101 complexed with HIV immunodominant epitope KM2(TAFTIPSI) |
Heteromer P12499; P61769; | 90.58 | ||||
| Crystal Structure of SB27 TCR in complex with the 'restriction triad' mutant HLA-B*3508-13mer |
Heteromer A0A5B9; P01848; P03206; P61769; | 92.03 | 7×IOD; | |||
| Structure of HD14 TCR in complex with HLA-B7 presenting an EBV epitope |
Heteromer P12977; P61769; | 100 | 1×PEG; 3×EDO; | |||
| Crystal structure of HLA-B*5201 in complexed with HIV immunodominant epitope (TAFTIPSI) |
Heteromer P12499; P61769; | 90.58 | ||||
| TCR589 in complex with HIV(Pol448-456)/HLA-B35 |
Heteromer K7N5M4; P04585; P61769; Q6IRV4; | 91.94 | 1×NAG; 3×ZN; 1×NAG; | |||
| Crystal Structure of the DM1 TCR in complex with HLA-B*4405 and decamer EBV antigen |
Heteromer P01848; P01850; P03204; P61769; | 89.13 | ||||
| Structure of a nested set of N-terminally extended MHC I-peptides provides novel insights into anti… |
Heteromer P61769; | 95.27 | ||||
| Crystal Structure of HLA-B*57:01 with a modified HIV peptide RKV-Kyn |
Heteromer P04578; P61769; | 89.82 | 1×ACT; | |||
| Structure of a nested set of N-terminally extended MHC I-peptides provides novel insights into anti… |
Heteromer P61769; | 95.27 | ||||
| Crystal structure of HLA-B*07:02 in complex with an NY-ESO-1 peptide |
Heteromer P61769; P78358; | 100 | ||||
| STRUCTURE OF HLA-B*07:02 IN COMPLEX WITH SYNTHETIC PHOSPHONO-MLL PEPTIDE ANALOG |
Heteromer P61769; Q03164; | 100 | 4×GOL; 1×NA; | |||
| STRUCTURE OF HLA-B*07:02 IN COMPLEX WITH SYNTHETIC SULFO-MLL PEPTIDE ANALOG |
Heteromer P61769; Q03164; | 100 | 3×GOL; | |||
| Structure of a nested set of N-terminally extended MHC I-peptides provide novel insights into antig… |
Heteromer P61769; | 95.27 | ||||
| STRUCTURE OF HLA-B*07:02 IN COMPLEX WITH MLL(747-755) PHOSPHOPEPTIDE AND BOUND GLYCEROL |
Heteromer P61769; Q03164; | 100 | 7×GOL; | |||
| HLA-B*57:01-RVAQLENVYI in complex with abacavir |
Heteromer P61769; P62318; | 89.82 | 1×1KX; 1×SO4; | |||
| Structures of Three HIV-1 HLA-B5703-Peptide Complexes and Identification of Related HLAs Potentiall… |
Heteromer P61769; Q70A61; | 89.82 | ||||
| Structure of a nested set of N-terminally extended MHC I-peptides provide novel insights into antig… |
Heteromer P61769; | 95.27 | ||||
| HLA-B*57:01 presenting TSTTSVASSW |
Heteromer P61769; Q14679; | 89.82 | 1×GOL; | |||
| Crystal Structure of HLA-B0702-RFL9 |
Heteromer P12478; P61769; | 100 | ||||
| Crystal Structure of HLA-B7 with the HCMV pp65 peptide RPHERNGFTVL |
Heteromer P61769; Q6SW59; | 100 | 4×NI; 8×GOL; | |||
| STRUCTURE OF HLA-B*07:02 IN COMPLEX WITH MLL(747-755) PEPTIDE AND BOUND GLYCEROL |
Heteromer P61769; Q03164; | 100 | 5×GOL; | |||
| CRYSTAL STRUCTURE OF HLA-B*07:02 IN COMPLEX WITH MLL(747-755) PHOSPHOPEPTIDE |
Heteromer P61769; Q03164; | 100 | 1×GLC; | |||
| Crystal structure of HLA-B*57:01.I80N |
Heteromer P01834; P61769; | 90.18 | ||||
| KIR3DL1 in complex with HLA-B*5701 |
Heteromer P01834; P43629; P61769; | 89.82 | 3×NAG; | |||
| CRYSTAL STRUCTURE OF HLA-B*07:02 IN COMPLEX WITH MLL(747-755) PEPTIDE |
Heteromer P61769; Q03164; | 100 | 2×GOL; 1×CL; 1×NA; | |||
| HUMAN LEUKOCYTE ANTIGEN B*07:02 IN COMPLEX WITH MERS-COV EPITOPE N95-103 (A95S mutant) |
Heteromer K9N4V7; P61769; | 100 | 2×BCT; 2×PEG; 1×CL; | |||
| Crystal Structure of HLA-B0702-RL9 |
Heteromer P12478; P61769; | 100 | ||||
| STRUCTURE OF HLA-B*07:02 IN COMPLEX WITH DOT1L(998-1006) PHOSPHOPEPTIDE |
Heteromer P61769; Q8TEK3; | 100 | 1×GLC; | |||
| TCR55 in complex with HIV(Pol448-456)/HLA-B35 |
Heteromer K7N5M4; P04585; P61769; Q6IRV4; | 92.0 | 3×EDO; 5×SO4; | |||
| HLA-B*57:01-LTTKLTNTNI in complex with abacavir |
Heteromer P00403; P61769; | 89.82 | 1×1KX; | |||
| HLA-B*57:01 presenting SSTRGISQLW |
Heteromer P61769; Q96HA1; | 89.82 | 1×GOL; | |||
| Human leukocyte antigen B*07:02 in complex with SARS-CoV2 epitope IPRRNVATL |
Heteromer P0DTD1; P61769; | 100 | ||||
| Structural basis for recognition of SARS-CoV-2 conserved nucleocapside epitopes by dominant T cell … |
Heteromer P0DTC9; P61769; | 100 | 1×P6G; 1×PEG; 1×GOL; | |||
| HLA-B*57:01 complexed to pep-V and Abacavir |
Heteromer P61769; | 89.82 | 1×1KX; 1×CL; | |||
| Structures of Three HIV-1 HLA-B5703-Peptide Complexes and Identification of Related HLAs Potentiall… |
Heteromer P61769; Q70A61; | 89.82 | ||||
| KIR3DL1 in complex with HLA-B*57:01.I80T |
Heteromer P01834; P43629; P61769; | 89.82 | 3×NAG; | |||
| KIR3DL1 in complex with HLA-B*57:01-TW10 |
Heteromer P03366; P43629; P61769; | 89.82 | 3×NAG; | |||
| Crystal structure of the KFJ5 TCR-NY-ESO-1-HLA-B*07:02 complex |
Heteromer A0A0B4J268; A0A5B6; P61769; P78358; | 100.0 | ||||
| STRUCTURE OF HLA-B*07:02 IN COMPLEX WITH DOT1L(998-1006) PEPTIDE |
Heteromer P61769; Q8TEK3; | 100 | 1×GLC; 1×NA; | |||
| KIR3DL1 in complex with HLA-B*57:01 presenting TSNLQEQIGW |
Heteromer P03366; P43629; P61769; | 89.82 | 3×NAG; | |||
| STRUCTURE OF HLA-B*07:02 IN COMPLEX WITH MLL(747-755) PHOSPHOPEPTIDE, CUBIC CRYSTAL FORM |
Heteromer P61769; Q03164; | 100 | 1×12P; 1×PE8; 2×PGE; 1×PEG; 1×PG4; 1×ACT; 1×1PE; | |||
| Crystal structure of HLA-B*07:02 with wild-type IDH2 peptide |
Heteromer P48735; P61769; | 100 | 4×PEG; 1×1PE; 2×SO4; 1×PGE; | |||
| Human leukocyte antigen B*07:02 in complex with SARS-CoV2 epitope SPRWYFYYL |
Heteromer P59595; P61769; | 100 | 1×P6G; | |||
| KIR3DL1*005 in complex with HLA-B*57:01 |
Heteromer P01834; P43629; P61769; | 89.82 | 3×NAG; | |||
| HLA B7:02 with HPNGYKSLSTL |
Heteromer P12601; P61769; | 100 | 3×EDO; 1×PEG; | |||
| HUMAN LEUKOCYTE ANTIGEN B*07:02 IN COMPLEX WITH SARS-COV2 EPITOPE N105-113 (Y111F mutant) |
Heteromer P0DTC9; P61769; | 100 | 1×PGE; 1×PG4; 3×CL; | |||
| Crystal Structure of HLA-B*5701, presenting the self peptide, LSSPVTKSF |
Heteromer P01834; P61769; | 89.82 | 4×GOL; | |||
| KIR3DL1*015 in complex with HLA-B*57:01 |
Heteromer P01834; P43629; P61769; | 89.82 | 3×NAG; | |||
| Crystal structure of HLA-B*4103 in complex with a 16mer self-peptide derived from heterogeneous nuc… |
Heteromer P07910; P61769; | 93.07 | 2×ACT; | |||
| Structures of Three HIV-1 HLA-B5703-Peptide Complexes and Identification of Related HLAs Potentiall… |
Heteromer P61769; Q8URG0; | 89.78 | ||||
| Crystal Structure of HLA-B5703 and HIV-1 peptide |
Heteromer P61769; Q9IDV9; | 89.42 | ||||
| Crystal structure of HLA-b46 at 1.6 angstrom resolution |
Heteromer P17763; P61769; | 93.8 | 3×NA; | |||
| TCR55 in complex with Pep20/HLA-B35 |
Heteromer K7N5M4; P61769; Q6IRV4; | 91.97 | 27×GOL; 4×PO4; | |||
| An Nt-acetylated peptide complexed with HLA-B*3901 |
Heteromer O00571; P61769; | 94.53 | ||||
| Crystal structure of HLA-B*4104 in complex with a 11mer self-peptide derived from S-methyl-5-thioad… |
Heteromer P61769; Q13126; | 93.43 | ||||
| A peptide complexed with HLA-B*3901 |
Heteromer O00571; P61769; | 94.53 | ||||
| Structural features underlying T-cell receptor sensitivity to concealed MHC class I micropolymorphi… |
Heteromer P61769; Q70XD7; | 89.78 | ||||
| A peptide complexed with HLA-B*3901 |
Heteromer O00571; P61769; | 94.53 | ||||
| Structural features underlying T-cell receptor sensitivity to concealed MHC class I micropolymorphi… |
Heteromer P61769; Q70XD7; | 89.78 | ||||
| Crystal structure of the KFJ37 TCR-NY-ESO-1-HLA-B*07:02 complex |
Heteromer A0A0B4J1U6; A0A0B4J268; P61769; P78358; | 100.0 | ||||
| Structural basis for recognition of SARS-CoV-2 conserved nucleocapside epitopes by dominant T cell … |
Heteromer P0DTC9; P61769; | 100.0 | 5×SO4; 1×GOL; | |||
| The crystal structure of a self-peptide complexed to Abacavir and HLA-B*57:01 |
Heteromer O00267; P61769; | 89.74 | 1×1KX; | |||
| Structural basis for recognition of SARS-CoV-2 conserved nucleocapside epitopes by dominant T cell … |
Heteromer P0DTC9; P61769; | 100 | ||||
1 SWISS-MODEL model
| Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 6at5.1.A | monomer | 0.87 | 100.00 | |||